Journal article icon

Journal article

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Abstract:

Background

Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor (PI) plus raltegravir (RAL) as an alternative second-line combination. We assessed whether this offers any advantage over the standard PI plus two nucleoside-reverse-transcriptase-inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme s...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/S1473-3099(17)30630-8

Authors


Thompson, JA More by this author
Kambugu, A More by this author
Expand authors...
European and Developing Countries Clinical Trials Partnership More from this funder
Medical Research Council More from this funder
Institito de Salud Carlos III More from this funder
Swedish International Development Cooperation Agency More from this funder
Expand funders...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Infectious Diseases Journal website
Volume:
18
Issue:
1
Pages:
47-57
Publication date:
2017-11-03
Acceptance date:
2017-10-05
DOI:
EISSN:
1474-4457
ISSN:
1473-3099
Pubs id:
pubs:734451
URN:
uri:0c5be2c4-4a7d-4395-a093-b952c8b5bfd9
UUID:
uuid:0c5be2c4-4a7d-4395-a093-b952c8b5bfd9
Local pid:
pubs:734451

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP